PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: a systematic review and meta-analysis

Jennings, D. L., Sultan, L., Mingov, J., Choe, J., Latif, F., Restaino, S., Clerkin, K., Habal, M. V., Colombo, P. C., Yuzefpulskaya, M., Sayer, G., Uriel, N., & Baker, W. L. (2022). PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: a systematic review and meta-analysis. Heart Failure Reviews, 28(1), 149–156. https://doi.org/10.1007/s10741-022-10255-5
Authors:
Douglas L Jennings
Lina Sultan
Jennifer Mingov
Jason Choe
Farhana Latif
Susan Restaino
Kevin Clerkin
Marlena V Habal
Paolo C Colombo
Melana Yuzefpulskaya
Gabriel Sayer
Nir Uriel
William L Baker
Affiliated Authors:
Douglas L Jennings
Jason Choe
Farhana Latif
Susan Restaino
Kevin Clerkin
Marlena V Habal
Paolo C Colombo
Melana Yuzefpulskaya
Gabriel Sayer
Nir Uriel
Columbia Affiliation:
Subjects:
Heart Transplantation (MeSH)
Hydroxymethylglutaryl-CoA Reductase Inhibitors (MeSH)
PCSK9 Inhibitors (MeSH)
Author Keywords:
alirocumab
evolocumab
heart transplant
statin intolerance
elink
Publication Type:
Article
Unique ID:
10.1007/s10741-022-10255-5
PMID:
35687219
DOI:
10.1007/s10741-022-10255-5
Journal:
Heart Failure Reviews
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record

Record Created: